drugset / Trial / NCT00538694

Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia

NCT00538694

Phase 3 Completed Merck & Co., Inc.
RandomizedParallel-groupDouble-blind

Summary

To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.

Timeline

Start
2000-10-31
Primary completion
2001-09-30
Completion
2001-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 4 mg/kg Intravenous

Indications